Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation

Imagem de Miniatura
Arquivos
art_RANDI_Measles_mumps_and_rubella_vaccine_12_months_after_.PDF (131.28 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Autores
FERNANDES, Eder Gatti
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.65, article ID e21, 4p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The measles, mumps and rubella (MMR) vaccine is usually recommended from 24 months after a hematopoietic stem cell transplant (HSCT). Some authors have demonstrated that the MMR vaccination can be safe from 12 months post-HSCT in non-immunosuppressed patients, as recommended by the Brazilian National Immunization Program/Ministry of Health, since 2006. The objectives of this study were to evaluate when patients received MMR vaccine after an HSCT in our care service and if there were reports of any side effects. We retrospectively reviewed the records of HSCT recipients who received at least one MMR dose in our care service, a quaternary teaching hospital in Sao Paulo city, Brazil, from 2017 to 2021. We identified 82 patients: 75.6% (90.1% in the autologous group and 45.1% in the allogeneic group) were vaccinated before 23 months post-transplantation. None reported side effects following the vaccination. Our data support that the MMR vaccination is safe from 12 to 23 months after HSCT.
Palavras-chave
Measles-mumps-rubella vaccine, MMR vaccine, Hematopoietic stem cell transplantation, Measles, Transplantation
URI
https://observatorio.fm.usp.br/handle/OPI/52956
Referências
  1. Brasil. Ministerio da Sande, 2022, B EPIDEMIOL, V53, P1
  2. Camargo M C, 2000, Rev Panam Salud Publica, V7, P359
  3. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices, GEN BEST PRACTICE GU
  4. Cordonnier C, 2019, LANCET INFECT DIS, V19, pE200, DOI 10.1016/S1473-3099(18)30600-5
  5. Desjardins M, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab504
  6. Ge YL, 2017, CHINESE MED J-PEKING, V130, P1320, DOI 10.4103/0366-6999.206358
  7. Hersh BS, 2000, LANCET, V355, P1943, DOI 10.1016/S0140-6736(00)02325-4
  8. Machado CM, 2005, BONE MARROW TRANSPL, V35, P787, DOI 10.1038/sj.bmt.1704878
  9. Machado CM, 2002, BLOOD, V99, P83, DOI 10.1182/blood.V99.1.83
  10. Misin A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8020276
  11. Oliveira MI, 2002, EMERG INFECT DIS, V8, P808, DOI 10.3201/eid0808.020040
  12. Pergam Steven A, 2019, Biol Blood Marrow Transplant, V25, pe321, DOI 10.1016/j.bbmt.2019.07.034
  13. Prevots DR, 2003, J INFECT DIS, V187, pS111, DOI 10.1086/368030
  14. Siqueira MM, 2001, J MED VIROL, V63, P299, DOI 10.1002/1096-9071(200104)63:4<299::AID-JMV1005>3.0.CO;2-3
  15. Waldman EA, 2011, REV SAUDE PUBL, V45, P173, DOI 10.1590/S0034-89102011000100020

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - LIM/48
Artigos e Materiais de Revistas Científicas - LIM/49
Carregar mais